Apr 1, 2021 5:10pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 15, 2021 6:00am EDT Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
Mar 10, 2021 4:30pm EST Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update